← Leaderboards
Markella V. Zanni
Massachusetts General Hospital
$10,033,281
Attributed
$15,166,181
Total exposure
8
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.6M · FY2010–25$5M$3.8M$2.5M$1.3M$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$15,166,181 · 8
By mechanism
R01$14,139,658 · 6
K24$907,875 · 1
F32$118,648 · 1
Top collaborators
- Chris Todd Longenecker5 shared
- Sara Elizabeth Dolan Looby5 shared
- Ntobeko Ayanda Bubele Ntusi5 shared
- Tomas G Neilan4 shared
- Kristine Mace Erlandson1 shared
- Jordan E Lake1 shared
Most similar at Massachusetts General Hospital
Same institution · by research overlap
- Steven Kyle Grinspoon$75,757,679
- Robert B Colvin$10,797,986
- Madhusmita Misra$12,646,884
- Christina Psaros$5,839,764
- Michael Tse-Yin Lu$4,120,399
Others in their field
Top investigators on “Cardiovascular System”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Chanza Baytop · Westat, Inc.$271,217,917
- Judith S. Currier · University Of California Los Angeles$139,907,800
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$137,892,773
- Judith S Hochman · New York University School Of Medicine$110,228,771
Research focus
Cardiovascular SystemPreventImmuneInflammationWomanImmune ActivationWomen&AposFunctional DisorderAgingCardiacPathway InteractionsFutureCardiovascular DiseasesEventUnited States National Institutes Of HealthInflammatoryReproductive SenescenceRandomized TrialHormonalViralRisk FactorsInnovationDesignParticipant
Grant awards (28)
Incretin Microdosing for Cardiometabolic Health in People With HIV: The REINFORCE Trial$966,521
R01 · FY2025 · DK
Effects of SGLT2 Inhibition on Coronary Flow Reserve and Other Key Indices Relevant to Type 2 Myocardial Infarction Risk among Women with HIV$752,558
R01 · FY2025 · HL · contact PI
Myocardial Fibrosis and Steatosis Burden and Region-Specific Predictors of Progression among ART-treated Women with HIV infection in sub-Saharan Africa (The MUTIMA Study)$260,998
R01 · FY2025 · HL
Myocardial Fibrosis and Steatosis Burden and Region-Specific Predictors of Progression among ART-treated Women with HIV infection in sub-Saharan Africa (The MUTIMA Study)$220,424
R01 · FY2025 · HL
Consequences of Persistent Immune Activation among ART-treated Women with HIV$181,575
K24 · FY2025 · AI · contact PI
Myocardial Fibrosis and Steatosis Burden and Region-Specific Predictors of Progression among ART-treated Women with HIV infection in sub-Saharan Africa (The MUTIMA Study)$169,960
R01 · FY2025 · HL
Effects of SGLT2 Inhibition on Coronary Flow Reserve and Other Key Indices Relevant to Type 2 Myocardial Infarction Risk among Women with HIV$771,613
R01 · FY2024 · HL · contact PI
Myocardial Fibrosis and Steatosis Burden and Region-Specific Predictors of Progression among ART-treated Women with HIV infection in sub-Saharan Africa (The MUTIMA Study)$743,216
R01 · FY2024 · HL
Consequences of Persistent Immune Activation among ART-treated Women with HIV$181,575
K24 · FY2024 · AI · contact PI
Myocardial Fibrosis and Steatosis Burden and Region-Specific Predictors of Progression among ART-treated Women with HIV infection in sub-Saharan Africa (The MUTIMA Study)$749,390
R01 · FY2023 · HL
Consequences of Persistent Immune Activation among ART-treated Women with HIV$181,575
K24 · FY2023 · AI · contact PI
Arterial Inflammation and Coronary Microvascular Dysfunction among Women with HIV: Missing Pieces to the MI Risk Puzzle$833,297
R01 · FY2022 · HL · contact PI
Consequences of Persistent Immune Activation among ART-treated Women with HIV$181,575
K24 · FY2022 · AI · contact PI
Arterial Inflammation and Coronary Microvascular Dysfunction among Women with HIV: Missing Pieces to the MI Risk Puzzle$833,296
R01 · FY2021 · HL · contact PI
Consequences of Persistent Immune Activation among ART-treated Women with HIV$181,575
K24 · FY2021 · AI · contact PI
Arterial Inflammation and Coronary Microvascular Dysfunction among Women with HIV: Missing Pieces to the MI Risk Puzzle$833,296
R01 · FY2020 · HL · contact PI
Mechanisms of Cardiac Dysfunction in HIV and the Effect of Statins$659,315
R01 · FY2020 · HL
Arterial Inflammation and Coronary Microvascular Dysfunction among Women with HIV: Missing Pieces to the MI Risk Puzzle$886,634
R01 · FY2019 · HL · contact PI
Cardiovascular Disease Risk in HIV-infected Women: Sex-Specific Mechanisms of Risk and Risk Reduction among REPRIEVE Trial Participants$743,401
R01 · FY2019 · AI · contact PI
Mechanisms of Cardiac Dysfunction in HIV and the Effect of Statins$663,909
R01 · FY2019 · HL
Cardiovascular Disease Risk in HIV-infected Women: Sex-Specific Mechanisms of Risk and Risk Reduction among REPRIEVE Trial Participants$740,154
R01 · FY2018 · AI · contact PI
Mechanisms of Cardiac Dysfunction in HIV and the Effect of Statins$683,840
R01 · FY2018 · HL
Cardiovascular Disease Risk in HIV-infected Women: Sex-Specific Mechanisms of Risk and Risk Reduction among REPRIEVE Trial Participants$738,035
R01 · FY2017 · AI · contact PI
Mechanisms of Cardiac Dysfunction in HIV and the Effect of Statins$708,470
R01 · FY2017 · HL
Cardiovascular Disease Risk in HIV-infected Women: Sex-Specific Mechanisms of Risk and Risk Reduction among REPRIEVE Trial Participants$747,720
R01 · FY2016 · AI · contact PI
Cardiovascular Disease Risk in HIV-infected Women: Sex-Specific Mechanisms of Risk and Risk Reduction among REPRIEVE Trial Participants$433,611
R01 · FY2015 · AI · contact PI
Effects of TNF-a Antagonism in Patients with Obesity and Metabolic Dysregulation$60,962
F32 · FY2011 · DK · contact PI
Effects of TNF-alpha Antagonism in Patients with Obesity and Metabolic Dysregulat$57,686
F32 · FY2010 · DK · contact PI